secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K/A
Filed at:   2024-01-11T23:59:59+00:00
Accession:  0001193125-24-006614
Event type: m_and_a
Sentiment:  negative
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aileron provides Lung Therapeutics financials: net loss $19M in 2022, accumulated deficit $63M, going concern cited
--------------------------------------------------------------------------------

- Lung Therapeutics net loss $19.0M in 2022, $9.9M in 2021; cash and equivalents $11.9M at Dec 31, 2022.
- Accumulated deficit $63.4M; auditor's report includes substantial doubt about going concern.
- Lung's lead candidate LTI-03 (IPF) in Phase 1b; LTI-01 (LPE) completed Phase 2.
- Pro forma condensed combined financial statements also filed with this 8-K/A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524006614/0001193125-24-006614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524006614/d22567d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-006614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer